Literature DB >> 1538256

Oxygen consumption and mixed venous oxygen saturation monitoring during orthotopic liver transplantation.

B D Spiess1, K J Tuman, R J McCarthy, W G Logas, T R Lubenow, J Williams, H Sankray, P Foster.   

Abstract

Mixed venous oxygen saturation (SvO2) monitoring has been advocated for some critically ill patients. Patients with end-stage hepatic failure have oxygen consumption rates that are lower than normal. Using the Fick equation, oxygen consumption may be calculated if mixed venous and arterial oxygen tensions (and saturations), hemoglobin, and cardiac output are determined simultaneously. This report describes a unique pattern of changes in SvO2 and oxygen consumption in 7 patients undergoing liver transplantation. A previous study correlated plasma carbohydrate (glucose) levels with early hepatic graft survival. After induction, the 7 patients reported here had low oxygen consumption and high SvO2 values. The oxygen consumption rates decreased to the lowest point during the anhepatic phase and rose above baseline by the end of the case. The SvO2 and oxygen consumption data reported here follow the presence of presumed hepatic metabolic activity (increased CO2 and ionized calcium). Further research must be completed to determine whether these measurements indicate early hepatic nonfunction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538256     DOI: 10.1007/bf01618080

Source DB:  PubMed          Journal:  J Clin Monit        ISSN: 0748-1977


  13 in total

1.  PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES.

Authors:  R P AMES; A J BORKOWSKI; A M SICINSKI; J H LARAGH
Journal:  J Clin Invest       Date:  1965-07       Impact factor: 14.808

2.  Prognostic significance of reperfusion hyperglycemia during liver transplantation.

Authors:  S V Mallett; Y Kang; J A Freeman; S Aggarwal; T Gasior; F L Fortunato
Journal:  Anesth Analg       Date:  1989-02       Impact factor: 5.108

3.  Oxygen consumption in critically-ill surgical patients.

Authors:  R F Wilson; C Christensen; L P LeBlanc
Journal:  Ann Surg       Date:  1972-12       Impact factor: 12.969

4.  Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation.

Authors:  Y G Kang; D J Martin; J Marquez; J H Lewis; F A Bontempo; B W Shaw; T E Starzl; P M Winter
Journal:  Anesth Analg       Date:  1985-09       Impact factor: 5.108

5.  Continuous monitoring of mixed venous oxygen saturation in critically ill patients.

Authors:  P L Baele; J C McMichan; H M Marsh; J C Sill; P A Southorn
Journal:  Anesth Analg       Date:  1982-06       Impact factor: 5.108

6.  Cardiovascular depression secondary to ionic hypocalcemia during hepatic transplantation in humans.

Authors:  J Marquez; D Martin; M A Virji; Y G Kang; V S Warty; B Shaw; J J Sassano; P Waterman; P M Winter; M R Pinsky
Journal:  Anesthesiology       Date:  1986-11       Impact factor: 7.892

7.  Continuous monitoring of mixed venous oxygen saturation in cardiac surgery.

Authors:  W R Jamieson; K W Turnbull; A J Larrieu; W A Dodds; J C Allison; G F Tyers
Journal:  Can J Surg       Date:  1982-09       Impact factor: 2.089

8.  Use of continuous monitoring of mixed venous saturation in the coronary care unit.

Authors:  J M Gore; K Sloan
Journal:  Chest       Date:  1984-11       Impact factor: 9.410

9.  Anesthesia for pediatric orthotopic liver transplantation.

Authors:  L M Borland; M Roule; D R Cook
Journal:  Anesth Analg       Date:  1985-02       Impact factor: 5.108

10.  Pulmonary aspects of chronic liver disease and liver transplantation.

Authors:  M J Krowka; D A Cortese
Journal:  Mayo Clin Proc       Date:  1985-06       Impact factor: 7.616

View more
  1 in total

1.  Hemodynamic and oxygen delivery-consumption changes during partial liver resection.

Authors:  H Iwasaka; T Kitano; A Mizutani; K Taniguchi; N Honda; Y I Kim; M Kobayashi
Journal:  J Anesth       Date:  1993-04       Impact factor: 2.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.